For a study, researchers sought to examine whether ubiquinol and d-ribose would lessen heart failure with preserved ejection fraction (HFpEF) patients’ symptoms and improve their cardiac performance. It was a phase 2 randomized, double-blind, placebo-controlled trial involving 216 patients with HFpEF with an ejection fraction (EF) of more than or equal to 50%. Group 1 received placebo ubiquinol capsules and d-ribose powder, Group 2 received ubiquinol capsules (600 mg/d) and placebo d-ribose powder, Group 3 received placebo ubiquinol capsules and d-ribose powder (15 g/d), and Group 4 received ubiquinol capsules and d-ribose powder. The study included 7 outcome measures: the Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score, the level of vigor as measured by a subscale from the Profile of Mood States, the ejection fraction (EF), the ratio of mitral peak velocity of early filling to early diastolic mitral annular velocity (septal E/e’ ratio), B-type natriuretic peptides, lactate/adenosine triphosphate ratio Treatment with ubiquinol and d-ribose significantly improved the KCCQ clinical summary score (17.30 to 25.82 points), the vigor score (7.65 to 8.15 points), and the EF (7.08% to 8.03%) as well as decreased B-type natriuretic peptides (−72.02 to −47.51) and lactate/adenosine triphosphate ratio (−4.32 to −3.35 × 10−4). There were no statistically significant changes in septal E/e′ or the 6-minute walk test. In conclusion, ubiquinol and d-ribose decreased HFpEF symptoms and raised EF. These data suggested that individuals with HFpEF might benefit from adding these supplements to routine therapeutic regimens.
- Business of Medicine
- Doctor’s Voice